Jaguar Health, Inc.

For the period ended Mar 31, 2026. Filed May 20, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 20, 2026

JAGX$0.44+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

March 31, · December 31,
(In thousands, except share and per share data) · 2026 · 2025
(unaudited)
Assets
Current assets:
Cash	$	7,278	$	968
Restricted cash		2,786		6,864
Accounts receivable, net		68		1,521
Other receivable		212		177
Inventory, net		7,819		8,599
Prepaid expenses and other current assets		2,047		2,216
Total current assets		20,210		20,345
Property and equipment, net		423		463
Operating lease - right-of-use asset		1,079		1,000
Intangible assets, net		15,553		16,021
Other assets		169		494
Total assets	$	37,434	$	38,323
Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable	$	4,957	$	8,686
Accrued liabilities		3,751		4,166
Deferred revenue		170		170
Operating lease liability, current		261		192
Notes payable, net of discount (includes note designated at Fair Value Option amounting to $18.9 million as of March 31, 2026, and $26.2 million as of December 31, 2025, respectively)		22,077		27,440
Series O Convertible Preferred stock: $0.0001 par value; 1,557,000 and 0 shares authorized at March 31, 2026 and December 31, 2025, respectively; 1,241,928 and 0 shares issued and outstanding at March 31, 2026 and December 31, 2025		9,470		—
Total current liabilities		40,686		40,654
Operating lease liability, net of current portion		898		892
Deferred revenue, net of current portion		340		382
Derivative liability		187		—
Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $7.6 million as of March 31, 2026, and $5.7 million as of December 31, 2025, respectively)		11,075		15,083
Total liabilities		53,186		57,011
Commitments and contingencies (See Note 5)
Stockholders' deficit
Series L perpetual preferred stock: $0.0001 par value; 200 shares designated from 4,475,074 preferred stock authorized at March 31, 2026, and December 31, 2025; 0 and 121 shares issued and outstanding at March 31, 2026 and December 31, 2025		—		2,485
Series M perpetual preferred stock: $0.0001 par value; 400 shares designated from 4,475,074 preferred stock authorized at March 31, 2026, and December 31, 2025; 0 and 144 shares issued and outstanding at March 31, 2026 and December 31, 2025		—		—
Series N perpetual preferred stock: $0.0001 par value; 951 shares designated from 4,475,074 preferred stock authorized at March 31, 2026, and December 31, 2025; 0 and 10 shares issued and outstanding at March 31, 2026 and December 31, 2025		—		—
Common stock - voting: $0.0001 par value, 298,000,000 shares authorized at March 31, 2026, and December 31, 2025; 371,980 and 199,330 issued and outstanding at March 31, 2026, and December 31, 2025, respectively		1		1
Common stock - non-voting: $0.0001 par value, 50,000,000 shares authorized at March 31, 2026, and December 31, 2025; 1 share issued and outstanding at March 31, 2026, and December 31, 2025		—		—
Additional paid-in capital		378,130		380,974
Noncontrolling interest		(1,574)		(1,399)
Accumulated deficit		(391,067)		(399,916)
Accumulated other comprehensive loss		(1,242)		(833)
Total stockholders' deficit		(15,752)		(18,688)
Total liabilities and stockholders' deficit	$	37,434	$	38,323

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.